Business Description
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.86 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -53.6 | |||||
3-Year EPS without NRI Growth Rate | -53.6 | |||||
3-Year FCF Growth Rate | -71.9 | |||||
3-Year Book Growth Rate | 112.1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 21.9 | |||||
9-Day RSI | 33.48 | |||||
14-Day RSI | 40.41 | |||||
6-1 Month Momentum % | -2.17 | |||||
12-1 Month Momentum % | -15.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.55 | |||||
Quick Ratio | 5.55 | |||||
Cash Ratio | 2.27 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.4 | |||||
Shareholder Yield % | -14.88 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -46.09 | |||||
ROA % | -35.48 | |||||
ROIC % | -63.71 | |||||
3-Year ROIIC % | 3003.86 | |||||
ROC (Joel Greenblatt) % | -912.15 | |||||
ROCE % | -46.08 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 7.64 | |||||
Price-to-Tangible-Book | 9.21 | |||||
EV-to-EBIT | -15.51 | |||||
EV-to-EBITDA | -15.67 | |||||
EV-to-FCF | -7.36 | |||||
Price-to-Net-Current-Asset-Value | 9.66 | |||||
Price-to-Net-Cash | 36 | |||||
Earnings Yield (Greenblatt) % | -6.44 | |||||
FCF Yield % | -14.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Abera Bioscience AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | |||
EPS (TTM) (kr) | -0.23 | ||
Beta | 0 | ||
Volatility % | 44.65 | ||
14-Day RSI | 40.41 | ||
14-Day ATR (kr) | 0.296779 | ||
20-Day SMA (kr) | 4.2895 | ||
12-1 Month Momentum % | -15.73 | ||
52-Week Range (kr) | 3.51 - 7.5 | ||
Shares Outstanding (Mil) | 15.35 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Abera Bioscience AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Abera Bioscience AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Abera Bioscience AB Frequently Asked Questions
What is Abera Bioscience AB(XSAT:ABERA)'s stock price today?
When is next earnings date of Abera Bioscience AB(XSAT:ABERA)?
Does Abera Bioscience AB(XSAT:ABERA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |